Cargando…

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelly, Donal T., Harding, Adam C., Gilbert-Jaramillo, Javier, Knight, Michael L., Longet, Stephanie, Brown, Anthony, Adele, Sandra, Adland, Emily, Brown, Helen, Tipton, Tom, Stafford, Lizzie, Mentzer, Alexander J., Johnson, Síle A., Amini, Ali, Tan, Tiong Kit, Schimanski, Lisa, Huang, Kuan-Ying A., Rijal, Pramila, Frater, John, Goulder, Philip, Conlon, Christopher P., Jeffery, Katie, Dold, Christina, Pollard, Andrew J., Sigal, Alex, de Oliveira, Tulio, Townsend, Alain R., Klenerman, Paul, Dunachie, Susanna J., Barnes, Eleanor, Carroll, Miles W., James, William S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371089/
https://www.ncbi.nlm.nih.gov/pubmed/34404775
http://dx.doi.org/10.1038/s41467-021-25167-5
_version_ 1783739567374860288
author Skelly, Donal T.
Harding, Adam C.
Gilbert-Jaramillo, Javier
Knight, Michael L.
Longet, Stephanie
Brown, Anthony
Adele, Sandra
Adland, Emily
Brown, Helen
Tipton, Tom
Stafford, Lizzie
Mentzer, Alexander J.
Johnson, Síle A.
Amini, Ali
Tan, Tiong Kit
Schimanski, Lisa
Huang, Kuan-Ying A.
Rijal, Pramila
Frater, John
Goulder, Philip
Conlon, Christopher P.
Jeffery, Katie
Dold, Christina
Pollard, Andrew J.
Sigal, Alex
de Oliveira, Tulio
Townsend, Alain R.
Klenerman, Paul
Dunachie, Susanna J.
Barnes, Eleanor
Carroll, Miles W.
James, William S.
author_facet Skelly, Donal T.
Harding, Adam C.
Gilbert-Jaramillo, Javier
Knight, Michael L.
Longet, Stephanie
Brown, Anthony
Adele, Sandra
Adland, Emily
Brown, Helen
Tipton, Tom
Stafford, Lizzie
Mentzer, Alexander J.
Johnson, Síle A.
Amini, Ali
Tan, Tiong Kit
Schimanski, Lisa
Huang, Kuan-Ying A.
Rijal, Pramila
Frater, John
Goulder, Philip
Conlon, Christopher P.
Jeffery, Katie
Dold, Christina
Pollard, Andrew J.
Sigal, Alex
de Oliveira, Tulio
Townsend, Alain R.
Klenerman, Paul
Dunachie, Susanna J.
Barnes, Eleanor
Carroll, Miles W.
James, William S.
author_sort Skelly, Donal T.
collection PubMed
description The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants.
format Online
Article
Text
id pubmed-8371089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83710892021-09-02 Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern Skelly, Donal T. Harding, Adam C. Gilbert-Jaramillo, Javier Knight, Michael L. Longet, Stephanie Brown, Anthony Adele, Sandra Adland, Emily Brown, Helen Tipton, Tom Stafford, Lizzie Mentzer, Alexander J. Johnson, Síle A. Amini, Ali Tan, Tiong Kit Schimanski, Lisa Huang, Kuan-Ying A. Rijal, Pramila Frater, John Goulder, Philip Conlon, Christopher P. Jeffery, Katie Dold, Christina Pollard, Andrew J. Sigal, Alex de Oliveira, Tulio Townsend, Alain R. Klenerman, Paul Dunachie, Susanna J. Barnes, Eleanor Carroll, Miles W. James, William S. Nat Commun Article The extent to which immune responses to natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants of concern (VOC) is of increasing importance. Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. We show that neutralization of the VOC compared to a reference isolate of the original circulating lineage, B, is reduced: more profoundly against B.1.351 than for B.1.1.7, and in responses to infection or a single dose of vaccine than to a second dose of vaccine. Importantly, high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and other emergent variants. Nature Publishing Group UK 2021-08-17 /pmc/articles/PMC8371089/ /pubmed/34404775 http://dx.doi.org/10.1038/s41467-021-25167-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Skelly, Donal T.
Harding, Adam C.
Gilbert-Jaramillo, Javier
Knight, Michael L.
Longet, Stephanie
Brown, Anthony
Adele, Sandra
Adland, Emily
Brown, Helen
Tipton, Tom
Stafford, Lizzie
Mentzer, Alexander J.
Johnson, Síle A.
Amini, Ali
Tan, Tiong Kit
Schimanski, Lisa
Huang, Kuan-Ying A.
Rijal, Pramila
Frater, John
Goulder, Philip
Conlon, Christopher P.
Jeffery, Katie
Dold, Christina
Pollard, Andrew J.
Sigal, Alex
de Oliveira, Tulio
Townsend, Alain R.
Klenerman, Paul
Dunachie, Susanna J.
Barnes, Eleanor
Carroll, Miles W.
James, William S.
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
title Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
title_full Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
title_fullStr Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
title_full_unstemmed Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
title_short Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
title_sort two doses of sars-cov-2 vaccination induce robust immune responses to emerging sars-cov-2 variants of concern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371089/
https://www.ncbi.nlm.nih.gov/pubmed/34404775
http://dx.doi.org/10.1038/s41467-021-25167-5
work_keys_str_mv AT skellydonalt twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT hardingadamc twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT gilbertjaramillojavier twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT knightmichaell twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT longetstephanie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT brownanthony twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT adelesandra twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT adlandemily twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT brownhelen twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT tiptontom twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT staffordlizzie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT mentzeralexanderj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT johnsonsilea twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT aminiali twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT tantiongkit twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT schimanskilisa twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT huangkuanyinga twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT rijalpramila twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT fraterjohn twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT goulderphilip twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT conlonchristopherp twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT jefferykatie twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT doldchristina twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT pollardandrewj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT sigalalex twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT deoliveiratulio twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT townsendalainr twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT klenermanpaul twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT dunachiesusannaj twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT barneseleanor twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT carrollmilesw twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern
AT jameswilliams twodosesofsarscov2vaccinationinducerobustimmuneresponsestoemergingsarscov2variantsofconcern